These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 19849892)

  • 1. Improvement of executive functions in boys with attention deficit hyperactivity disorder: an open-label follow-up study with once-daily atomoxetine.
    Gau SS; Shang CY
    Int J Neuropsychopharmacol; 2010 Mar; 13(2):243-56. PubMed ID: 19849892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A head-to-head randomized clinical trial of methylphenidate and atomoxetine treatment for executive function in adults with attention-deficit hyperactivity disorder.
    Ni HC; Shang CY; Gau SS; Lin YJ; Huang HC; Yang LK
    Int J Neuropsychopharmacol; 2013 Oct; 16(9):1959-73. PubMed ID: 23672818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving visual memory, attention, and school function with atomoxetine in boys with attention-deficit/hyperactivity disorder.
    Shang CY; Gau SS
    J Child Adolesc Psychopharmacol; 2012 Oct; 22(5):353-63. PubMed ID: 23083022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of atomoxetine on executive functioning and lexical decision in attention-deficit/hyperactivity disorder and reading disorder.
    de Jong CG; Van De Voorde S; Roeyers H; Raymaekers R; Allen AJ; Knijff S; Verhelst H; Temmink AH; Smit LM; Rodriques-Pereira R; Vandenberghe D; van Welsen I; ter Schuren L; Al-Hakim M; Amin A; Vlasveld L; Oosterlaan J; Sergeant JA
    J Child Adolesc Psychopharmacol; 2009 Dec; 19(6):699-707. PubMed ID: 20035588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential Treatment Effects of Methylphenidate and Atomoxetine on Executive Functions in Children with Attention-Deficit/Hyperactivity Disorder.
    Wu CS; Shang CY; Lin HY; Gau SS
    J Child Adolesc Psychopharmacol; 2021 Apr; 31(3):187-196. PubMed ID: 33890819
    [No Abstract]   [Full Text] [Related]  

  • 6. Atomoxetine improved attention in children and adolescents with attention-deficit/hyperactivity disorder and dyslexia in a 16 week, acute, randomized, double-blind trial.
    Wietecha L; Williams D; Shaywitz S; Shaywitz B; Hooper SR; Wigal SB; Dunn D; McBurnett K
    J Child Adolesc Psychopharmacol; 2013 Nov; 23(9):605-13. PubMed ID: 24206099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Executive function in adults with attention-deficit/hyperactivity disorder during treatment with atomoxetine in a randomized, placebo-controlled, withdrawal study.
    Adler L; Tanaka Y; Williams D; Trzepacz PT; Goto T; Allen AJ; Escobar R; Upadhyaya HP
    J Clin Psychopharmacol; 2014 Aug; 34(4):461-6. PubMed ID: 24977716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial.
    Durell TM; Adler LA; Williams DW; Deldar A; McGough JJ; Glaser PE; Rubin RL; Pigott TA; Sarkis EH; Fox BK
    J Clin Psychopharmacol; 2013 Feb; 33(1):45-54. PubMed ID: 23277268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationships Between Functional Outcomes and Symptomatic Improvement in Atomoxetine-Treated Adult Patients with Attention-Deficit/Hyperactivity Disorder: Post Hoc Analysis of an Integrated Database.
    De Bruyckere K; Bushe C; Bartel C; Berggren L; Kan CC; Dittmann RW
    CNS Drugs; 2016 Jun; 30(6):541-58. PubMed ID: 27224994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/hyperactivity disorder.
    Gau SS; Huang YS; Soong WT; Chou MC; Chou WJ; Shang CY; Tseng WL; Allen AJ; Lee P
    J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):447-60. PubMed ID: 17822340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative study of OROS-MPH and atomoxetine on executive function improvement in ADHD: a randomized controlled trial.
    Yang L; Cao Q; Shuai L; Li H; Chan RC; Wang Y
    Int J Neuropsychopharmacol; 2012 Feb; 15(1):15-26. PubMed ID: 22017969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atomoxetine and neuropsychological function in children with attention-deficit/hyperactivity disorder: results of a pilot study.
    Maziade M; Rouleau N; Lee B; Rogers A; Davis L; Dickson R
    J Child Adolesc Psychopharmacol; 2009 Dec; 19(6):709-18. PubMed ID: 20035589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder.
    Schulz KP; Fan J; Bédard AC; Clerkin SM; Ivanov I; Tang CY; Halperin JM; Newcorn JH
    Arch Gen Psychiatry; 2012 Sep; 69(9):952-61. PubMed ID: 22945622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atomoxetine effects on executive function as measured by the BRIEF--a in young adults with ADHD: a randomized, double-blind, placebo-controlled study.
    Adler LA; Clemow DB; Williams DW; Durell TM
    PLoS One; 2014; 9(8):e104175. PubMed ID: 25148243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Atomoxetine and Osmotic Release Oral System-Methylphenidate on Executive Functions in Patients with Combined Type Attention-Deficit/Hyperactivity Disorder.
    Ince Tasdelen B; Karakaya E; Oztop DB
    J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):494-500. PubMed ID: 26218871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atomoxetine as an adjunct therapy in the treatment of co-morbid attention-deficit/hyperactivity disorder in children and adolescents with bipolar I or II disorder.
    Chang K; Nayar D; Howe M; Rana M
    J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):547-51. PubMed ID: 19877979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Open-label atomoxetine for attention-deficit/ hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders.
    Posey DJ; Wiegand RE; Wilkerson J; Maynard M; Stigler KA; McDougle CJ
    J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):599-610. PubMed ID: 17069548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of atomoxetine on executive function impairments in adults with ADHD.
    Brown TE; Holdnack J; Saylor K; Adler L; Spencer T; Williams DW; Padival AK; Schuh K; Trzepacz PT; Kelsey D
    J Atten Disord; 2011 Feb; 15(2):130-8. PubMed ID: 20026871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.
    Dittmann RW; Schacht A; Helsberg K; Schneider-Fresenius C; Lehmann M; Lehmkuhl G; Wehmeier PM
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):97-110. PubMed ID: 21488751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atomoxetine and methylphenidate treatment in children with ADHD: the efficacy, tolerability and effects on executive functions.
    Yildiz O; Sismanlar SG; Memik NC; Karakaya I; Agaoglu B
    Child Psychiatry Hum Dev; 2011 Jun; 42(3):257-69. PubMed ID: 21165694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.